Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2026-09-08 | Reverse | 1:20 |
| 2014-12-05 | Reverse | 1:25 |
Cytosorbents develops blood purification devices like CytoSorb for sepsis, critical care, organ preservation, and blood safety, along with veterinary, renal, and contrast removal technologies.
CytoSorbents' flagship CytoSorb is an EU-approved extracorporeal cytokine adsorber targeting severe inflammation, with the U.S. focus on gaining approval for its DrugSorb-ATR device.
In a pivotal series of events for CytoSorbents, the U.S. Food and Drug Administration (FDA) issued a De Novo Denial Letter for its DrugSorb-ATR device on April 25, 2025, citing the need for additional information. Following an appeal process, the FDA upheld its denial in August 2025 but found no issues with the device's safety and proposed a potential path forward. This culminated in the company's September 16, 2025, announcement that it would submit a new De Novo application, a decision that created a new, albeit delayed, pathway to potential U.S. market authorization and significantly influenced investor sentiment throughout the year.
In a significant strategic move to improve financial performance, Cytosorbents announced a comprehensive restructuring plan in the third quarter of 2025. This initiative includes a workforce reduction of approximately 10% and a realignment of production and operating expenses to accelerate the company's timeline to achieving operating cash flow break-even.
Cytosorbents (NASDAQ: CTSO - Get Free Report) and Zynex (NASDAQ: ZYXI - Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, earnings, institutional ownership, risk and valuation. Risk and Volatility Cytosorbents has a beta of 1.34,
PRINCETON, N.J., Sept. 30, 2026 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces upcoming data presentations using CytoSorb® in open heart surgery at the European Association for Cardio-Thoracic Surgery (EACTS) Annual Meeting in Barcelona, Spain from October 7-10, 2026 and in critical care at the European Society of Intensive Care Medicine (ESICM) Annual Congress in Lisbon, Portugal from October 10-14, 2026.
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 BDSX | $27.61 | COMPARE |
 ECOR | $10.06 | COMPARE |
 TELO | $1.25 | COMPARE |
 MDAI | $1.67 | COMPARE |
 TELA | $1.18 | COMPARE |
 SRTS | $3.00 | COMPARE |
 BDMD | $0.75 | COMPARE |
 SER | $2.04 | COMPARE |
